Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001493152-22-006175
Filing Date
2022-03-07
Accepted
2022-03-07 16:05:42
Documents
14
Period of Report
2022-03-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-ka.htm   iXBRL 8-K/A 46491
2 logo_11.jpg GRAPHIC 15620
3 ex10-1.htm EX-10.1 74207
  Complete submission text file 0001493152-22-006175.txt   354744

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lpcn-20220307.xsd EX-101.SCH 3033
5 XBRL LABEL FILE lpcn-20220307_lab.xml EX-101.LAB 34476
6 XBRL PRESENTATION FILE lpcn-20220307_pre.xml EX-101.PRE 22595
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-ka_htm.xml XML 3721
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

EIN.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36357 | Film No.: 22718028
SIC: 2834 Pharmaceutical Preparations